Colorectal Pulmonary Metastases: Pulmonary Metastasectomy or Stereotactic Radiotherapy?
RCT
SABR
colorectal lung metastases
oligometastatic colorectal cancer
pulmonary metastasectomy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Oct 2023
28 Oct 2023
Historique:
received:
12
09
2023
revised:
16
10
2023
accepted:
25
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Pulmonary metastasectomy and stereotactic ablative radiotherapy (SABR) are both guideline-recommended treatments for selected patients with oligometastatic colorectal pulmonary metastases. However, there is limited evidence comparing these local treatment modalities in similar patient groups. We retrospectively reviewed records of consecutive patients treated for colorectal pulmonary metastases with surgical metastasectomy or SABR from 2012 to 2019 at two Dutch referral hospitals that had different approaches toward the local treatment of colorectal pulmonary metastases, one preferring surgery, the other preferring SABR. Two comparable patient groups were identified based on tumor and treatment characteristics. The metastasectomy group comprised 40 patients treated for 69 metastases, and the SABR group had 60 patients who were treated for 90 metastases. Median follow-up was 38 months (IQR: 26-67) in the surgery group and 46 months (IQR: 30-79) in the SABR group. Median OS was 58 months (CI: 20-94) in the metastasectomy group and 70 months (CI: 29-111) in the SABR group ( In this retrospective cohort study, pulmonary metastasectomy and SABR had comparable overall survival, local recurrence-free survival, and complication rates, despite patients in the SABR group having a significantly lower progression-free survival and local control rate. These data would support a randomized controlled trial comparing surgery and SABR in operable patients with radically resectable colorectal pulmonary metastases.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary metastasectomy and stereotactic ablative radiotherapy (SABR) are both guideline-recommended treatments for selected patients with oligometastatic colorectal pulmonary metastases. However, there is limited evidence comparing these local treatment modalities in similar patient groups.
METHODS
METHODS
We retrospectively reviewed records of consecutive patients treated for colorectal pulmonary metastases with surgical metastasectomy or SABR from 2012 to 2019 at two Dutch referral hospitals that had different approaches toward the local treatment of colorectal pulmonary metastases, one preferring surgery, the other preferring SABR. Two comparable patient groups were identified based on tumor and treatment characteristics.
RESULTS
RESULTS
The metastasectomy group comprised 40 patients treated for 69 metastases, and the SABR group had 60 patients who were treated for 90 metastases. Median follow-up was 38 months (IQR: 26-67) in the surgery group and 46 months (IQR: 30-79) in the SABR group. Median OS was 58 months (CI: 20-94) in the metastasectomy group and 70 months (CI: 29-111) in the SABR group (
CONCLUSION
CONCLUSIONS
In this retrospective cohort study, pulmonary metastasectomy and SABR had comparable overall survival, local recurrence-free survival, and complication rates, despite patients in the SABR group having a significantly lower progression-free survival and local control rate. These data would support a randomized controlled trial comparing surgery and SABR in operable patients with radically resectable colorectal pulmonary metastases.
Identifiants
pubmed: 37958360
pii: cancers15215186
doi: 10.3390/cancers15215186
pmc: PMC10647532
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Thorac Surg. 2019 Feb;107(2):631-649
pubmed: 30476477
J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49
pubmed: 9011700
Clin Oncol (R Coll Radiol). 2016 Aug;28(8):505-12
pubmed: 26899780
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):419-427
pubmed: 28463162
Br J Surg. 2020 Jul;107(8):943-945
pubmed: 32386092
Colorectal Dis. 2020 Oct;22(10):1314-1324
pubmed: 32388895
Clin Lung Cancer. 2016 Sep;17(5):e141-e149
pubmed: 26791542
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1044-1052
pubmed: 26025776
HPB (Oxford). 2022 Oct;24(10):1651-1658
pubmed: 35501243
Colorectal Dis. 2021 Jul;23(7):1793-1803
pubmed: 33783109
Ann Oncol. 2023 Jan;34(1):10-32
pubmed: 36307056
Cancers (Basel). 2021 Aug 26;13(17):
pubmed: 34503113
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Eur J Cardiothorac Surg. 2020 Oct 1;58(4):768-774
pubmed: 32282876
J Radiat Res. 2020 Nov 16;61(6):935-944
pubmed: 32940330
J Hematol Oncol. 2019 Feb 14;12(1):16
pubmed: 30764882
J Clin Oncol. 2020 Sep 1;38(25):2830-2838
pubmed: 32484754
J Thorac Cardiovasc Surg. 2019 Oct;158(4):1234-1241.e16
pubmed: 31395367
Radiother Oncol. 2022 Feb;167:187-194
pubmed: 34952002
Thorac Cancer. 2018 Dec;9(12):1671-1679
pubmed: 30298701
Radiother Oncol. 2022 Jan;166:92-99
pubmed: 34748855
Interdiscip Cardiovasc Thorac Surg. 2023 Feb 6;36(2):
pubmed: 36847670
Br J Surg. 2010 Jul;97(7):1110-8
pubmed: 20632280
BMC Cancer. 2019 Feb 26;19(1):173
pubmed: 30808323
J Thorac Cardiovasc Surg. 2019 Apr;157(4):1648-1655
pubmed: 30635188
Colorectal Dis. 2021 Nov;23(11):2911-2922
pubmed: 34310835
J Thorac Oncol. 2017 Sep;12(9):1442-1445
pubmed: 28576747
Eur J Surg Oncol. 2015 Sep;41(9):1217-25
pubmed: 26095702
Eur J Cardiothorac Surg. 2021 May 8;59(5):996-1003
pubmed: 33230525